Eclosion Emerges to Fill A Swiss Start-Up Void
This article was originally published in Start Up
Executive SummaryDespite being home to renowned research institutions and universities and mid- to large-size biopharma companies, Geneva, Switzerland, midway through the last decade, still lacked what it considered a vibrant life sciences start-up scene. A few years later and the Swiss region’s all-hands-on deck approach to building one has birthed a new hybrid model, the public/private endeavor Eclosion, which is one part early-stage incubator and another part venture fund.
You may also be interested in...
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.